Board summary
Key figures
51,551
Registered population
60.0% aged 18–64
18.2%
Aged 65+
ICB 20.0% · England 17.9%
17.5%
Ethnic minority (non-White)
14.9% Asian · England 9.6%
50.9%
In IMD quintile 1
ICB 30.6% · England 21.0%
~26,472
Core20 residents (est.)
Resident basis; registered basis ~26,762 · see page 3
8,551
Hypertension register
+9.95% in 3 yrs · England +5.60%
632
SMI register
52.3% of Burnley's
1,493
COPD register
Reviews +12.81% in 3 yrs
Forecast to 2030
10,523
Hypertension patients, 2030
+1,972 on today
66.7%
QRISK ≥20% on statins, 2030
+1.38pp over 3 yrs
4.5%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma annual reviews trail local and national benchmarks.
Only 60.1% of 3,529 asthma patients had an annual review (Burnley 67.8%, ICB 65.0%, England 65.7%), leaving about 1,400 unreviewed.
Age-five MMR2 and pre-school boosters miss 95.0% target.
At age five, MMR coverage drops 8.1 pp from dose 1 (88.6%) to dose 2 (80.5%), matching 4-in-1 boosters (80.5%) below the 95.0% target.
COPD annual review coverage grew faster than England.
COPD annual review coverage rose +12.8% over 2023 to 2025 (Burnley +8.5%, ICB +1.3%, England +2.8%), reaching 73.9%.
Population, age and ethnicity
A list of 51,551 has higher child and Asian resident shares than England
Across 51,551 registered patients, children aged 0-17 comprise 21.8% (Burnley 22.5%, ICB 19.6%, England 19.6%), while patients aged 65+ make up 18.2% (9,383 patients; Burnley 16.7%, ICB 20.0%, England 17.9%). Census usual residents show an Asian or Asian British share of 14.9% (Burnley 14.7%, ICB 9.4%, England 9.6%), with Riverside Family Practice at 49.5%. Ethnicity figures reflect resident Census estimates rather than GP registrations. Projected list growth to 2030 is 1.5% under an unverified methodology (England 2.3%, Burnley 1.6%, ICB 1.7%).
Age profile
65+: ICB 20.0%, England 17.9%
Ethnicity
Older people · falls rows are Burnley local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Burnley LA) | 1,746 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 80.0% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 50.8% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Burnley LA) | 675 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Burnley LA) | 14.8 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation reaches 50.9% overall, spanning 38.8% to 83.0% across member practices
Across the PCN, 50.9% of registered patients live in Core20 areas (Burnley 52.5%, ICB 30.6%, England 21.0%), though weighted practice share is 51.9% with observation periods unstated. Practice concentration spans 44.3 pp, from 38.8% at Padiham Group Practice to 83.0% at Riverside Family Practice. Targeting by concentration highlights Riverside Family Practice (4,609 estimated Core20 patients), while Burnley Group Practice has the highest volume with 13,259 estimated patients. Outreach could balance high-concentration neighbourhood clinics with scaled recall across high-volume lists.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
632
SMI register
1.21% recorded prevalence
364
Learning disability register
0.70% recorded prevalence
38
Care homes, 1,123 beds
In the PCN catchment
9.9%
Provide unpaid care
Burnley, Census 2021
Recorded severe mental illness prevalence is 1.2% (632 patients; Burnley 1.1%, ICB 1.2%, England 1.0%) and learning disability prevalence is 0.7% (364 patients; Burnley 0.7%, ICB 0.6%, England 0.6%). The PCN catchment includes 38 care homes with 1,123 beds, though bed counts do not establish PCN registered occupancy. Crude prevalence does not establish unmet need or coding quality.
Severe mental illness: physical health checks
Severe mental illness prevalence is 1.2% (England 1.0%). Annual physical checks trail: blood pressure checks reach 77.0% (England 83.4%) and BMI recording is 73.3% (England 82.1%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
8,551
Hypertension register
+9.95%
Register growth, 3 yrs
Burnley +7.94% · England +5.60%
+0.99pp
BP control, under 80
≤140/90 · +1.17pp aged 80+
+1,972
More patients by 2030
Forecast 10,523 (19.83%)
Hypertension case-finding and control
Hypertension prevalence is 16.4% (8,551 patients), above England (15.2%) and Burnley (16.3%), but below NHS Lancashire and South Cumbria ICB (17.2%). However, recent blood pressure checks reach 84.9% against 90.0% nationally, and blood pressure control to <= 140/90 mmHg for patients under 80 is 64.1%, trailing Burnley (67.4%), the ICB (67.1%) and England (67.8%). For patients aged 80 and over, control is 79.3% against 81.2% in England. Denominators include personalised care adjustments, and crude prevalence does not establish undiagnosed disease. Blood pressure control falls below England and local comparators, suggesting that structured recall and therapy titration for patients under 80 could be prioritised to narrow the management gap.
Lipids and statins
Lipid-lowering therapy in patients with QRISK >= 20% is 63.9%, above England (63.6%) and the ICB (61.4%). In diabetes without CVD, statin coverage is 71.7%, below England (73.2%) and Burnley (72.4%). Statin coverage in diabetes without cardiovascular disease falls below England, suggesting routine diabetic reviews could prioritise lipid therapy initiation to close the preventive gap.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 109,824 | £1.40 | £1.64 | £1.86 | £153,754 |
| Cardiovascular (all), 2025 | 152,313 | £3.29 | £3.38 | £3.33 | £501,110 |
In 2026, the PCN prescribed 109,824 lipid-regulating drug items at £1.40 per item, below Burnley (£1.58), the ICB (£1.64) and England (£1.86), spending £50,519 less than at England's unit cost across 109,824 items. Prescribing unit costs remain below national benchmarks, suggesting pharmacy reviews can focus on treatment optimisation and adherence rather than drug expenditure.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−0.55%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−2.40%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 2.9% on a register of 1,493, above England (1.9%), with reviews reaching 73.9% (England 76.4%) after rising +12.8% over three years (England +2.8%). Asthma prevalence is 7.2% on a register of 3,529 (England 6.6%), but annual reviews lag at 60.1% (England 65.7%), leaving about 1,400 patients without a recorded annual review. Asthma management prescribing reaches 1,748 items per 1,000 aged 5-19 (England 1,488), while youth second-hand smoke status recording trails at 72.6% (England 78.8%).
Cancer register and children's immunisation
The cancer register records 2,029 patients (3.9% prevalence vs England 3.8%). In childhood immunisations, COVER Q1 2025/26 data shows MMR dose 1 at age 5 reaches 88.6% but MMR dose 2 falls to 80.5% (an 8.1 pp gap; England 82.8%), while 4-in-1 pre-school booster coverage is 80.5% (England 80.9%). Both pre-school boosters sit 14.5 pp below the 95.0% target, highlighting a clear need to improve pre-school booster follow-up.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
52.4%
Lancashire and South Cumbria ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,010
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Lancashire and South Cumbria ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 86.0% | 85.4% | 6% | 1,561 |
| Prostate | 42.4% | 53.2% | 11% | 1,404 |
| Lung | 31.1% | 33.8% | 15% | 1,374 |
| Bowel | 44.2% | 47.0% | 13% | 1,198 |
| Skin cancer | 86.1% | 87.8% | 21% | 519 |
In 2022, 52.4% of staged cancers across NHS Lancashire and South Cumbria ICB (4,642 of 8,863) were diagnosed at stage 1 or 2 (England 55.3%), sitting 22.6 pp below the 75.0% national ambition by 2028, with 74.6% staged overall (8,863 of 11,883). Staging data reflects wider system pathways rather than PCN delivery. Locally, Burnley West PCN recorded cervical screening coverage aged 25-49 of 62.9% (England 66.8%; 3-year change -3.4% vs England -1.0%) and breast screening coverage aged 53-70 of 67.3% (England 69.9%; 3-year change +1.8% vs England +8.4%).
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026, East Lancashire Hospitals NHS Trust achieved 73.2% on the 62-day cancer standard (11.8 pp below the 85.0% standard), ahead of England (71.2%) but behind the ICB (73.6%), Northern Care Alliance NHS Foundation Trust (78.6%) and Airedale NHS Foundation Trust (88.9%). The trust met the 28-day faster diagnosis standard at 81.5% (standard 75.0%; ICB 78.4%, England 79.3%) and the 31-day treatment standard at 98.1% (standard 96.0%; ICB 93.6%, England 92.5%). Diagnostic 6+ week waits were 0.4% for MRI and 0.1% for CT (England 21.4% and 9.9%). These acute provider metrics reflect wider system performance rather than PCN delivery.
| Pathways within standard (%) | East Lancashire | Northern Care Alliance | Airedale | Lancashire and South Cumbria ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 81.50 | 75.20 | 87.71 | 78.39 | 79.32 |
| 31-day treatment (96%) | 98.11 | 94.54 | 98.20 | 93.62 | 92.50 |
| 62-day referral to treatment (85%) | 73.16 | 78.65 | 88.89 | 73.62 | 71.16 |
| Diagnostic waits over 6 weeks (%) | East Lancashire | Northern Care Alliance | Airedale | England |
|---|---|---|---|---|
| MRI | 0.43 | 5.09 | 2.91 | 21.40 |
| CT | 0.15 | 4.10 | 0.00 | 9.92 |
| Echocardiography | 0.00 | 31.48 | 0.70 | 28.48 |
| Colonoscopy | 0.95 | 40.04 | 31.21 | 30.83 |
| Gastroscopy | 1.16 | 36.48 | 22.98 | 29.02 |
| All 15 DM01 tests | 3.25 | 15.71 | 4.33 | 23.14 |
| Community services activity | Lancashire residents | Lancashire and South Cumbria ICB |
|---|---|---|
| Care contacts | 126,445 | 193,720 |
| Referrals | 20,415 | 29,855 |
| Patients with a contact | 47,320 | 65,335 |
Community services (residents of Lancashire), Jun 2026 (provisional). In June 2026, provisional Community Services Data Set records show 126,445 total community contacts for Burnley borough residents. Adults aged 65 and over accounted for 72,000 of these contacts, or 56.9% of borough activity. These data reflect borough activity and are not published at PCN level.
Practice variation and patient experience
Practice variation and patient experience
Across 2025/26, QOF overall achievement ranged from 80.7% at Riverside Family Practice to 92.4% at Ightenhill Medical Centre (England 92.5%). Vaccination and immunisation achievement trailed England (55.2%) across all five practices, spanning a 17.5 pp range from 15.6% at Riverside Family Practice to 33.1% at Ightenhill Medical Centre.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Padiham | 131 | 38.8 | 49.1% | 68.0% | 72.4% |
| Riverside | 99 | 83.0 | 38.7% | 76.7% | 66.9% |
| Ightenhill | 108 | 60.3 | 59.2% | 69.1% | 65.9% |
| Rosegrove Surgery | 101 | 39.1 | 59.0% | 76.0% | 64.4% |
| Burnley | 89 | 53.8 | 23.8% | 63.6% | 61.7% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
18 of 25 measures trail England's three-year change, led by heart failure reviews
Across 25 tracked measures, 18 trail England's three-year change. The widest lag is in heart failure reviews (-13.5% vs England +8.7%, Burnley -3.6%, ICB +1.3%), alongside breast screening (+1.8% vs England +8.4%) and asthma reviews (-0.6% vs England +4.4%). Conversely, the PCN outpaced England in learning disability register growth (+13.9% vs England +5.4%), COPD reviews (+12.8% vs England +2.8%), hypertension blood pressure recording (+4.9% vs England +3.6%), and psychosis alcohol recording (+6.4 pp vs England +5.4 pp). These divergent trends could reflect uneven recall capacity, which clinical audit would test.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Breast screening (53-70)
Dementia register
COPD register
Asthma reviews
COPD reviews
Hypertension BP reading
Alcohol record (psychosis)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Burnley | Asset | PCN | Burnley |
|---|---|---|---|---|---|
| Care homes (catchment) | 38 (1,123 beds) | n/a | Schools (catchment) | 114 | n/a |
| Children's centres | 6 | 6 | Places of worship | 64 | 54 |
| Libraries | 7 | 6 | Homelessness support (VCS) | 1 | 1 |
| Primary schools (LA maintained) | 31 | 26 | Primary academies | 8 | 6 |
| Special schools | 2 | 2 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma annual review recall
Asthma reviews reach 60.1% of 3,529 patients (England 65.7%, Burnley 67.8%, ICB 65.0%; 3-year change -0.6% vs England +4.4%), leaving 1,409 (about 1,400) unreviewed. For discussion: run a single-template asthma recall combining inhaler checks with flexible review slots, starting in high-concentration and high-volume Core20 practices. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Pre-school MMR2 and booster recall
In Q1 2025/26 (149 five-year-olds), MMR dose 2 is 80.5% vs 88.6% for dose 1 (an 8.1 pp gap; ICB 87.4%, England 82.8%), with 4-in-1 booster uptake at 80.5%. Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Option 3
Combined SMI physical health checks
On an SMI register of 632 (1.2% vs England 1.0%), annual BP checks reach 77.0% (England 83.4%, Burnley 82.8%, ICB 79.8%) and BMI recording reaches 73.3% (England 82.1%). Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Culturally tailored practice outreach (p2) | Asian / Asian British | Neighbourhood health framework · Core20PLUS5 approach | PCN |
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical health checks (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension blood pressure control review (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall review (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Structured asthma annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Pre-school MMR2 and booster recall (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Option 3 · Combined SMI physical health checks (p12) | Severe mental illness register · Severe mental illness: QOF prevalence · SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
